Germany giant Merck (NYSE: MRK) struck a three-year partnership with Tsinghua Shenzhen International Graduate School, with a focus on the development of a new organoid 3D printing system. The tie-up is designed to develop bioengineering-based technologies to enable high-throughput and standardized organoid applications in academic research and the pharmaceutical industry. No financial details were disclosed.
Benefits of the Partnership
The partnership with Merck, well versed in the life science field, is conducive to applying the biological 3D printing organoid technology to high-throughput drug screening, and accelerating the technology from laboratory to industry.-Fineline Info & Tech
